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Abstract
A goal of personalized medicine is to provide increasingly sophisticated, individualized 
approaches to management and therapy for disease. Genetics is the engine that drives personalized 
medicine, holding the promise of therapeutics directed toward the unique needs of each patient. 
The 3rd International Conference on Cardiomyopathy in Children provided a forum to discuss the 
current status of personalized approaches to diagnosis, management, and therapy in the pediatric 
cardiomyopathy population. This review will focus on the importance of genetic diagnosis in this 
population as a necessary first step toward understanding the best approach to management and 
influencing disease outcome. The genetic heterogeneity of cardiomyopathy in children, the 
implications of specific genotypes, the ability to risk stratify based on genotype, and the impact on 
cascade screening in family members will be discussed.
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Introduction
The prognosis, response to treatment, and long term outcome of diseases with substantial 
phenotypic heterogeneity are difficult to predict. Heart muscle disease in infants and 
children has an extremely variable clinical course with differences in age of onset, response 
to medication, morbidity and mortality [1–7]. As a result, biomarkers that correlate with 
clinical outcome, screening that allows earlier identification of disease, genetic testing that 
allows risk stratification, and diagnostic testing that aids prediction of response to treatment 
are all approaches that are being intensively investigated with hopes of providing improved 
management and therapy. With advances in genetic diagnostics, the ability to identify the 
Address correspondence to: Stephanie M. Ware, MD, PhD, Indiana University School of Medicine, 1044 W. Walnut Street, 
Indianapolis, IN 46202, Ph: (317) 274-8938, Fax: (317) 274-8679, stware@iu.edu. 
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Prog Pediatr Cardiol. Author manuscript; available in PMC 2016 July 01.
Published in final edited form as:
Prog Pediatr Cardiol. 2015 July 1; 39(1): 43–47. doi:10.1016/j.ppedcard.2015.01.008.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
underlying cause of cardiomyopathy in pediatric patients has expanded tremendously. 
However, the large number of genetic causes of pediatric cardiomyopathy poses a challenge 
for diagnosis and limits the ability to understand phenotypic variability and longitudinal 
clinical course. We maintain that understanding genetic causation in this population is a 
necessary prerequisite toward the development of more specific therapy and an important 
aspect of creating increasingly personalized medical approaches.
Classification of pediatric cardiomyopathy and etiologic categories
As with adult cardiomyopathy, pediatric cardiomyopathy is typically classified by cardiac 
phenotype with five major classifications being recognized: hypertrophic cardiomyopathy 
(HCM), dilated cardiomyopathy (DCM), restrictive cardiomyopathy (RCM), 
arrhythmogenic right ventricular cardiomyopathy (ARVC), and left ventricular 
noncompaction cardiomyopathy (LVNC)[8]. The latter can be seen alone or in combination 
with other types of cardiomyopathy, frequently HCM or DCM. These diseases of the 
myocardium result in systolic dysfunction, diastolic dysfunction, or both, and the clinical 
taxonomy informs management but does not address the underlying etiology. In adults, 
HCM is considered a disease of the sarcomere, and is frequently caused by mutations in 
genes encoding the components of the contractile apparatus. With a prevalence of 1 in 500, 
HCM is the most common monogenic cardiac disorder [9]. Similarly, non-ischemic DCM is 
frequently genetic and can be caused by mutations in the contractile apparatus or 
cytoskeletal components of the myocyte.
Cardiomyopathy also affects infants and children, and while less prevalent than adult 
cardiomyopathy, it is a chronic and often progressive disease with significant morbidity. 
Forty percent of affected individuals progress to death or transplant within 5 years of 
diagnosis. In the pediatric population, cardiomyopathy is most frequently the result of 
genetic or infectious etiologies [10–12]. There is greater heterogeneity of genetic causes 
than seen in the adult population, despite similar phenotypic classes of cardiomyopathy. The 
ability to predict longitudinal clinical course and disease progression would provide new 
avenues for management and treatment.
In 1994, the Pediatric Cardiomyopathy Registry (PCMR) initiated studies on the 
epidemiologic features of cardiomyopathy in children with diagnostic categories that 
included myocarditis, inborn errors of metabolism, malformation syndromes, neuromuscular 
disease, familial, and unknown (idiopathic) causes [13]. These data pre-dated many clinically 
available genetic tests and up to 70% of cases were designated idiopathic, but these studies 
provided a useful framework for understanding the variable causes underlying pediatric 
cardiomyopathy. In 2012, we performed a single site study in order to determine the 
etiologic classification of pediatric cardiomyopathy cases when combining recent clinically 
available genetic testing and full evaluation by clinical geneticists [12]. This study indicated 
that while mutations in genes that underlie adult cardiomyopathy are common in the infant 
and pediatric populations, genetic syndromic cases and inborn errors of metabolism, 
including mitochondrial disorders, comprise up to 30% of causes. In the majority of cases, 
cardiac imaging does not provide information to assist with distinguishing the underlying 
etiology. Therefore, history, physical exam, and a comprehensive differential are necessary. 
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Importantly, patients with these disorders have medical management needs beyond their 
cardiac care needs and thus precise diagnosis of underlying etiology is critical to optimize 
treatment.
Benefits of a genetic diagnosis
Clinical genetic testing is currently available for HCM, DCM, RCM, ARVC, and LVNC in 
the form of large multi-gene panels. These panels primarily test sarcomeric and cytoskeletal 
gene mutations underlying “familial” cardiomyopathy in HCM, DCM, RCM, and LVNC, 
and test desmosomal genes in ARVC. Despite expanding gene panels, the yield of testing 
for HCM has not changed substantially since clinical testing became available in the United 
States. This is in part due to the fact that mutations in MYBPC3 and MYH7 account for the 
majority of cases of gene positive HCM. Unlike HCM, no gene(s) account for the majority 
of cases of gene positive DCM, although recent evidence suggests that mutations in TTN, 
encoding the large protein titin, may underlie up to 20% of cases [14]. However, 
interpretation of variants in this gene are problematic and there is some suggestion that TTN 
may function as a modifier in combination with other genetic variation. Currently, these 
large multigene panels do not include the most frequently identified causes of syndromic or 
metabolic disease in the pediatric population such as Noonan syndrome, Alstrom syndrome, 
Pompe disease or other storage disorders, or mitochondrial disorders. Thus, to investigate 
these potential causes, they must be considered in the differential of the infant or child with 
cardiomyopathy and appropriate diagnostic testing performed.
There are several benefits of obtaining a genetic diagnosis in patients with cardiomyopathy, 
including confirming the diagnosis in ambiguous cases, defining the etiologic basis in order 
to further guide management, and identifying at risk relatives. In cases where a definitive 
diagnosis is unclear, such as unexplained left ventricular hypertrophy, positive genetic 
testing resolves ambiguity and allows institution of appropriate screening and medical 
therapy, recommendations about physical activity, and institution of appropriate family 
surveillance. A limitation to this testing is the fact that negative results are not informative 
and do not rule out a genetic diagnosis.
A second benefit is accurately identifying etiology. This allows for the institution of 
appropriate cardiac screening and medical therapy, appropriate management and 
surveillance of other organ system involvement, provision of specific prognostic 
information, and institution of appropriate family screening and counseling. However, it is 
important to note that despite a comprehensive diagnostic evaluation, in some instances 
idiopathic cases remain. In addition, within the distinct etiologic categories, genotype-
phenotype correlations are variable and may not impact management.
A third benefit is the ability to identify at risk relatives, thus achieving important risk 
stratification and allowing cost-effective implementation of cardiac surveillance only in at 
risk individuals. In the Netherlands, the national healthcare system and the existence of a 
founder mutation in MYBPC3 has resulted in broadly instituted genetic testing for HCM 
with cascade genetic testing provided to first degree relatives [15, 16]. This has led to the 
diagnosis of presymptomatic individuals at risk for HCM. In the United States, a recent 
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study investigated the uptake of cardiac screening and genetic screening amongst 302 at risk 
family members of patients with HCM or DCM [17]. Not surprisingly, first degree relatives 
were more likely than second degree relatives to complete screening and testing. There was 
a statistically greater uptake of cardiac surveillance as compared to genetic testing, for 
unknown reasons. Importantly, 40% of asymptomatic relatives were given a genetic 
diagnosis and 25% were given a clinical diagnosis based on cardiac imaging. Potential 
consequences of this cascade screening are improved risk stratification, reduction in sudden 
cardiac death, improved understanding of early signs and symptoms and disease 
progression, and a reduction in healthcare costs. However, limitations include logistics for 
broad implementation and expense. In addition, more research is required to better 
understand specific motivations and barriers to genetic screening in this population, given 
the difference in uptake between genetic screening and cardiac screening.
Consensus guidelines on cardiac and genetic screening
Recommendations and consensus guidelines for management of cardiomyopathy 
incorporating genetic testing and screening of family members have emerged concomitant 
with the increasing availability of clinical genetic testing [18–22]. Educating patients and 
families about potential genetic etiologies and inheritance are important components. In 
addition, specific recommendations about cardiac screening of at-risk relatives and 
implications of clinical genetic testing should be provided. It is likely that the expertise for 
these services exists primarily at large academic medical centers.
A 2011 international consensus statement addressed genetic testing guidelines for the five 
major subtypes of cardiomyopathy (Table 1)[18]. In this document, based on expert option, 
the strongest recommendation for genetic testing is among patients with HCM where the 
positive predictive value of testing is high and genetic test results can aid in diagnosis and 
disease management.
HCM currently has the highest yield of genetic testing with mutations found in upwards of 
60% of cases. Therefore, comprehensive or targeted genetic testing is recommended (Class 
I) for any patient with a clinical diagnosis of HCM. Genetic testing is not currently 
recommended (Class III) in the evaluation of hypertrophy in an athlete’s heart.
For patients with DCM, genetic testing has a Class I recommendation in cases that also have 
significant conduction disease and/or a family history of premature sudden cardiac death. 
Otherwise for those with familial disease, genetic testing can be useful (Class IIa). Similarly, 
LVNC and ARVC genetic testing has a Class IIa recommendation. Specifically, ARVC 
genetic testing can be particularly problematic as some genetic variants have also been 
identified in 13.9–16% of normal, healthy volunteers[23]. Furthermore, many variants 
which were initially thought to either be pathogenic or benign have been reclassified making 
testing interpretation particularly challenging for this subclass. Genetic testing may be 
considered (Class IIb) in RCM, and several new causes of RCM have been identified since 
the publication of the consensus statement [24–26].
Mutation-specific cascade genetic testing is universally recommended for family members 
regardless of clinical status after a causative mutation is identified in an index case. This 
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recommendation is based on the potential for therapeutic or protective intervention in 
cardiomyopathy. It is also important to note that genetic counseling is recommended in all 
cases. There should be a thorough discussion of the different genetic testing options and the 
risks and benefits of such testing. Actual genetic practices vary from center to center and 
from physician to physician. Decisions to test or not are often tailored to each specific 
patient or family. Genetic testing may also be influenced by physician knowledge of clinical 
genetics and ease of genetic testing. Particularly in the pediatric population, genetic testing 
can be of great importance [9, 12, 19, 27]. Genetic test results can help refine risk 
stratification and can lead to earlier disease detection and treatment which is especially 
impactful in young children.
Those individuals who are asymptomatic but found to carry a disease-causing mutation 
should undergo routine clinical screening [20]. For HCM, screening is recommended every 
3 years during until age 30 and then every 5 years. During puberty, screening is increased to 
yearly. For DCM, LVNC, and RCM clinical screening is yearly in childhood and then every 
1–3 years in adulthood. For ARVC, screening is recommended on a yearly basis from age 
10 to 50 years. Again, actual clinical practices vary and should be tailored to each specific 
patient and family.
Current state of the art in genotype-phenotype correlations
A goal of personalized medicine is to apply specific management or therapy to a patients 
underlying cause of disease. In pediatric cardiomyopathy, the genetic basis of disease is 
increasingly identified, especially with comprehensive evaluation as discussed previously. 
The ability to tailor therapy to a specific genetic variant is not currently available and 
genotype-phenotype correlations are generally limited, in part because most families have 
unique, private mutations. In a few select cases there are certain genotype-phenotype 
correlations, but usually there are more exceptions than definitive rules. In HCM, MYBPC3 
mutations were initially reported to have a later age of onset with delayed clinical expression 
of disease until middle or old age with survival tending to be better than for other sarcomeric 
gene mutations. However, these results did not incorporate a large number of pediatric 
cases, and in our anecdotal experience, MYBPC3 mutations are as common in the pediatric 
population presenting with cardiomyopathy as MHY7 mutations. There does appear to be an 
association between mutation type and number with truncating mutations and more than one 
mutation being associated with greater disease severity [28, 29].
Patients with TNNT2 mutations have been reported with relatively small degrees of 
hypertrophy but with significant rhythm disturbances and a high incidence of sudden cardiac 
death. DES and LMNA mutations are also associated with an increased risk of sudden 
cardiac death [30]. LMNA is an example of a gene in which there is significant phenotypic 
heterogeneity depending on the site of the mutation. The group of disorders caused by 
mutations in this gene range from muscular dystrophies to premature aging syndromes. 
Patients with LMNA mutations may present with DCM with conduction system disease, or 
may have skeletal muscle myopathy in the form of limb girdle muscular dystrophy or 
Emery-Dreifuss muscular dystrophy. Some patients with LMNA mutations have ongoing 
risk for cardiometabolic derangement, including a lipodystrophic phenotype with truncal 
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adiposity, hyperinsulinemia, and liver dysfunction. Thus, specific clinical surveillance is 
indicated and patients with DCM resulting from specific LMNA variants would have 
different management based on their genotype than patients with DCM resulting from, for 
example, MYH7 variants. In ARVC, PKP2 mutations seem to be associated with an earlier 
onset of arrhythmias [31]. Mutations in PKP2, DES, or LMNA should prompt consideration 
for more frequent screening or even prophylactic defibrillator placement. As a final 
example, mutations in DSP, a desmosomal gene, cause ARVC in approximately 90% of 
cases and DCM in 10%. All DCM mutations in DSP to date are missense mutations. 
Because the evaluation, surveillance, and management recommendations differ for DCM 
versus ARVC, these potential genotype-phenotype correlations are important.
Despite some advances, there is still much that needs to be understood in terms of the 
molecular mechanisms that help determine disease phenotype. Current research efforts are 
aimed at advancing our understanding of genotype-phenotype correlations including a 
current NHLBI pediatric study looking at genetic modifiers in patients with known disease 
causing mutations.
Case Examples
Case 1
An 11-year-old boy was referred to cardiology for a murmur. On history, he previously had 
surgery for myringotomy tubes and surgery for unilateral cryptorchidism. On physical exam, 
the patient was noted to be in the fifth percentile for height. He had downslanting palpebral 
fissures with ptosis. He had a low posterior hairline with webbing of the neck. A 15-lead 
electrocardiogram (ECG) showed normal sinus rhythm, northwest axis, and an incomplete 
right bundle branch block. Echocardiogram showed a mid-septal bulge of asymmetric 
hypertrophy without obstruction.
This patient was referred for genetic testing for suspicion of a Noonan-related syndrome. On 
further discussion with the parents, they admitted they could never figure out why he was so 
much shorter than his siblings. In addition, while the patient was in a regular class at school 
he did have an individualized learning plan in place as there were some scholastic 
difficulties. This case illustrates how genetic syndromes can often be missed especially 
when children are young and phenotypic characteristics are subtle. In this case, genetic 
testing could help to unify the patient’s constellations of findings under a single diagnosis. 
Having the proper genetic diagnosis is important as the management strategies may differ 
when there are extracardiac issues to also consider. The growth, genitourinary, and cognitive 
issues associated with Noonan syndrome are all illustrated in this vignette. However, 
hematologic, oncologic, lymphatic, and other issues are also seen in patients with 
RASopathies and these could impact cardiac care.
A diagnosis of a genetic syndrome associated with HCM has significant implications for the 
patient. First, there are health supervision guidelines for a number of genetic syndromes 
associated with cardiac disease, including Noonan syndrome [32]. While some patients with 
Noonan syndrome have classic physical and facial features, it is not uncommon for Noonan 
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syndrome to be diagnosed in adolescents or young adults who were presumed to have 
isolated HCM.
Noonan syndrome and associated RASopathies are commonly associated with HCM. 
However, as opposed to cardiomyopathy caused by sarcomeric gene mutations, Noonan 
syndrome tends to also be associated with valvular issues which may require balloon 
valvuloplasty, surgery, or other intervention. Even individuals without any heart disease 
should continue to have periodic lifelong cardiac evaluation as cardiac findings can develop 
at any time. Intervals for cardiac evaluation need to take these factors into account.
Furthermore, as a large subset of Noonan syndrome is de novo, familial testing and 
screening strategies differ than in cases of familial isolated cardiomyopathy which are 
primarily due to autosomal dominantly inherited mutations in the sarcomeric genes. 
Evaluation of both parents is warranted with particular attention to the stereotypic features 
of Noonan syndrome. This may require referral to a clinical geneticist or other specialist. In 
cases that are due to a de novo mutation, testing or screening of siblings is not required.
Finally, the pathway dysregulated in Noonan syndrome, the RAS/MAPK signal transduction 
pathway, has effects that are distinct from those dysregulated by sarcomeric gene mutations. 
Some recent studies with Noonan mouse models have shown promising results in the 
reversal of HCM by pathway modulation, suggesting that therapeutic approaches more 
specific to this disease process may be on the horizon [33, 34].
Case 2
An 18-year-old male with HCM was seen in cardiology clinic. His family history was 
significant for a mother who was diagnosed with HCM at the age of 39. ECG showed sinus 
rhythm with evidence of preexcitation. There was T wave inversion in lateral and inferior 
leads and ST depression in lateral leads. Cardiac MRI showed severe hypertrophy with a 
maximal diastolic ventricular septal thickness of 34 mm. Delayed myocardial enhancement 
imaging demonstrated patchy areas of delayed enhancement. Genetic testing revealed a 
sarcomeric mutation.
The younger 17-year-old brother was subsequently also referred to cardiology. His ECG 
also showed preexcitation but was otherwise normal. Echocardiogram showed possible 
asymmetric hypertrophy, although quantitative measurements were very inconsistent and 
ranged from normal to abnormal. Based on clinical imaging it was unclear if this was the 
beginning of HCM or possibility normal hypertrophy in response to exercise as the younger 
brother was a soccer player. Mutation-specific genetic testing was sent in the brother.
This scenario illustrates the value of family-based genetic screening. In this particular case, 
it could help make the diagnosis HCM and inform recommendations regarding sports. In 
addition, it can also help identify other family member who may be at risk. Furthermore, for 
those that test negative it can remove the need for continued clinical screening.
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Case 3
A six-year-old female was referred for heart transplant evaluation. She had initially 
presented at the age of four with congestive heart failure in the setting of presumed acute 
myocarditis. She also had marked liver and renal impairment initially which then gradually 
improved. On physical exam she had extreme failure to thrive with preserved height but 
weight dramatically below the fifth percentile. Her liver was enlarged 5 cm below the right 
costal margin. No other dysmorphic features were noted. ECG demonstrated normal sinus 
rhythm with first degree atrioventricular block, left axis deviation, left ventricular 
hypertrophy with strain pattern, T wave inversions with ST segment depression in the lateral 
leads, and possible biatiral enlargement. Transthoracic echocardiogram showed a severely 
dilated left ventricle with poor left ventricular function (ejection fraction 22–23%; normal 
56–78%). Both atria were mildly dilated as was the right ventricle with borderline 
hypertrophy and mildly decreased function. She had mild-to-moderate tricuspid and mitral 
regurgitation. Right heart catheterization revealed elevated right heart pressures with high 
pulmonary vascular resistance at 7 Woods units x m2. Cardiac biopsy pathology found 
storage material which was consistent with a polysaccharide. Based on suspicion for a 
glycogen storage disease specific genetic testing was sent.
This case demonstrates the etiological heterogeneity that exists especially within pediatric 
cardiomyopathy. In pediatrics, DCM is frequently thought to be due to myocarditis when in 
fact it could be due to an underlying genetic disease such as a neuromuscular disease, or, as 
in this case, a metabolic disorder. Moreover, at times it is difficult to distinguish if other 
organ system involvement is primary or secondary to the heart failure. In this particular 
scenario, a key component of the clinical management and an ongoing cardiac transplant 
evaluation was the molecular diagnosis. Knowledge of extracardiac disease could greatly 
alter medical decision making and the clinical treatment plan.
Summary
Pediatric cardiomyopathy poses unique challenges because it is rare and because its causes 
are more heterogeneous than adult cardiomyopathy. Genetic testing is an important 
component of the diagnostic evaluation of patients with cardiomyopathy and the risk 
stratification of the family members. Currently, cardiac management is directed toward the 
phenotype rather than being directed toward the underlying cause. For example, a patient 
with HCM would initially be treated similarly regardless of whether the underlying cause 
was Noonan syndrome, a mitochondrial disorder, or an MYH7 mutation. Nevertheless, we 
know that a correct etiologic diagnosis is necessary to provide the optimal care for all the 
medical issues of the patient, to be proactive in healthcare supervision, and to apply 
appropriate family based cardiac and/or genetic screening to identify at risk family 
members. Therefore, genetic diagnosis plays an important role in overall patient 
management. Providing increasingly sophisticated, personalized approaches to cardiac 
management and therapy for disease is an active area of ongoing research and will require 
additional clinical longitudinal studies.
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Table 1
Summary of expert consensus recommendations from The Heart Rhythm Society and the 
European Heart Rhythm Association[18]
Classification is as follows: Class I “is recommended,” Class IIa “can be useful,” and Class IIb “may be 
considered.”
Class I Class IIa Class IIb
Hypertrophic cardiomyopathy
Patient with clinical diagnosis X
Cascade testing in family members X
Dilated cardiomyopathy
Patient with familial disease X
Patient with clinical diagnosis and conduction disease and/or family history of premature sudden cardiac 
death
X
Cascade testing in family members X
Left ventricular noncompaction cardiomyopathy
Patient with clinical diagnosis X
Cascade testing in family members X
Restrictive cardiomyopathy
Patient with clinical diagnosis X
Cascade testing in family members X
Arrhythmogenic right ventricular cardiomyopathy
Patient with clinical diagnosis X
Cascade testing in family members X
Prog Pediatr Cardiol. Author manuscript; available in PMC 2016 July 01.
